SLC5A2 and hydrops fetalis: The encouraging data on MACE and HF from the first SGLT2 inhibitor trials led to the design and carrying out of new clinical studies to investigate the efficacy of SGLT2 inhibitors in diabetic and non-diabetic patients with HF.